Effect of potassium chloride supplements on upper gastrointestinal mucosa
Effect of potassium chloride supplements on upper gastrointestinal mucosa
复制标题
氯化钾补充剂对上消化道粘膜的影响
DOI：
10.1038/clpt.1984.124
复制
发表时间：
1984
影响因子：
6.7
通讯作者：
Atilla Elian
中科院分区：
文献类型：
--
作者：
F. Mcmahon;J. Ryan;K. Akdamar;Atilla Elian
为了评估口服氯化钾补充剂的上消化道安全性，我们进行了8项为期1周或2周的对照实验，涉及225名健康男性受试者，以及一项涉及18名高血压患者的研究，其中9名患者长期使用蜡基质氯化钾制剂。所有短期研究的受试者上胃肠道正常。受试者在接受以下三种常用处方中的一种治疗后至少7天再次接受检查：蜡基质KCl片、KCl液体、微胶囊KCl、钾抑制剂或安慰剂。一些人接受抗胆碱能药物治疗，以诱导胃运动延迟。控制饮食和对治疗方案的依从性。结果表明，上粘膜损伤，特别是糜烂（43%）和溃疡（11%），在蜡基质片后更常见。液体氯化钾（0%）、微囊化氯化钾（10.5%糜烂，1.2%溃疡）和保钾药物（0%）后，这些变化发生的频率要低得多。更严重和更频繁的病变与运动减慢有关。未见隐蔽性出血。症状性主诉与内窥镜检查结果无关。在长期研究中，高血压患者在KCl治疗19至23个月后接受内窥镜检查，1周后再次接受内窥镜检查。在接受蜡基质KCl补充剂治疗近2年的9例高血压患者中，有6例出现了显著病变。其中一人在7天后出现溃疡。在一组只接受安慰剂的对照组中，病变发生率较低（9人中有3人出现糜烂，没有人出现溃疡或发展成溃疡）。蜡基片剂的上粘膜损伤发生率高于其他液体或微胶囊形式的氯化钾或钾节约药物。
Eight controlled 1‐ or 2‐wk experiments involving 225 healthy male subjects and one study of 18 patients with hypertension, nine of whom were long‐term users of a wax‐matrix potassium chloride preparation, were conducted to evaluate the upper gastrointestinal safety of oral KCl supplements. All subjects in the short‐term studies had normal upper gastrointestinal tracts. Subjects were examined again after at least 7 days of treatment with one of three commonly prescribed wax‐matrix KCl tablets, KCl liquid, microencapsulated KCl, a potassium‐sparer, or placebo. Some received an anticholinergic drug with treatment to induce delayed gastric motility. Diet and compliance to treatment regimens were controlled. Results indicate that upper mucosal injury, particularly erosions (43%) and ulcerations (11%), were more frequent after wax‐matrix tablets. These changes occurred much less frequently after liquid KCl (0%), microencapsulated KCl (10.5% erosions, 1.2% ulcers), and the potassium‐sparing drug (0%). More serious and more frequent lesions were associated with slowed motility. No occult bleeding was noted. Symptomatic complaints did not correlate with endoscopic findings. In the long‐term study, patients with hypertension were examined endoscopically after 19 to 23 mo on KCl and again after 1 wk. Six of nine of the patients with hypertension treated for nearly 2 yr with a wax‐matrix KCl supplement had significant lesions. One had developed ulceration after 7 days. The incidence of lesions was lower in a carefully matched group of controls who received only placebo (erosions in three of nine; none had or developed ulcers). Incidence of upper mucosal injury with wax‐matrix tablets is higher than with other liquid or microencapsulated forms of KCl or with a potassium‐sparing drug.